$URGN
UroGen Pharma Ltd. Stock $urgn

$urgn Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000143774924033454 Filed on November 06, 2024

Income Statement

Concept	2024 Q4	2024 Q3
Revenue		$25.20M
YoY Change		20.87%
Cost Of Revenue		$2.453M
YoY Change		3.63%
Gross Profit		$22.75M
YoY Change		23.08%
Gross Profit Margin		90.27%
Selling, General & Admin		$28.94M
YoY Change		33.03%
% of Gross Profit		127.21%
Research & Development		$11.36M
YoY Change		11.0%
% of Gross Profit		49.91%
Depreciation & Amortization		$100.0K
YoY Change		-50.0%
% of Gross Profit		0.44%
Operating Expenses		$40.30M
YoY Change		25.98%
Operating Profit		-$17.55M
YoY Change		29.96%
Interest Expense		$36.00K
YoY Change		-101.21%
% of Operating Profit
Other Income/Expense, Net		-$158.0K
YoY Change		-322.54%
Pretax Income		-$23.58M
YoY Change		7.74%
Income Tax		$91.00K
% Of Pretax Income
Net Earnings		-$23.67M
YoY Change		8.2%
Net Earnings / Revenue		-93.93%
Basic Earnings Per Share		-$0.55
Diluted Earnings Per Share		-$0.55
COMMON SHARES
Basic Shares Outstanding	42.20M	42.11M
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$249.6M
YoY Change		69.3%
Cash & Equivalents		$124.9M
Short-Term Investments		$124.7M
Other Short-Term Assets		$15.13M
YoY Change		-9.96%
Inventory		$7.594M
Prepaid Expenses
Receivables		$22.80M
Other Receivables		$0.00
Total Short-Term Assets		$295.1M
YoY Change		62.03%
LONG-TERM ASSETS
Property, Plant & Equipment		$608.0K
YoY Change		-26.12%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$4.641M
YoY Change		-28.6%
Other Assets		$370.0K
YoY Change		-81.95%
Total Long-Term Assets		$6.846M
YoY Change		-40.52%
TOTAL ASSETS
Total Short-Term Assets		$295.1M
Total Long-Term Assets		$6.846M
Total Assets		$301.9M
YoY Change		55.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$5.556M
YoY Change		37.49%
Accrued Expenses		$23.98M
YoY Change		25.57%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$32.79M
YoY Change		27.14%
LONG-TERM LIABILITIES
Long-Term Debt		$121.7M
YoY Change		23.54%
Other Long-Term Liabilities		$121.9M
YoY Change		9.55%
Total Long-Term Liabilities		$121.7M
YoY Change		23.54%
TOTAL LIABILITIES
Total Short-Term Liabilities		$32.79M
Total Long-Term Liabilities		$121.7M
Total Liabilities		$276.4M
YoY Change		17.32%
SHAREHOLDERS EQUITY
Retained Earnings		-$768.7M
YoY Change		17.66%
Common Stock		$794.0M
YoY Change		29.85%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		$25.52M
YoY Change
Total Liabilities & Shareholders Equity		$301.9M
YoY Change		55.94%

Cashflow Statement

Concept	2024 Q4	2024 Q3
OPERATING ACTIVITIES
Net Income		-$23.67M
YoY Change		8.2%
Depreciation, Depletion And Amortization		$100.0K
YoY Change		-50.0%
Cash From Operating Activities		-$27.66M
YoY Change		59.91%
INVESTING ACTIVITIES
Capital Expenditures		$96.00K
YoY Change		-4.0%
Acquisitions
YoY Change
Other Investing Activities		-$106.7M
YoY Change		-21430.8%
Cash From Investing Activities		-$106.8M
YoY Change		-26787.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		39.61M
YoY Change		-65.88%
NET CHANGE
Cash From Operating Activities		-27.66M
Cash From Investing Activities		-106.8M
Cash From Financing Activities		39.61M
Net Change In Cash		-94.81M
YoY Change		-195.59%
FREE CASH FLOW
Cash From Operating Activities		-$27.66M
Capital Expenditures		$96.00K
Free Cash Flow		-$27.76M
YoY Change		59.54%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001668243
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-23673000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-21879000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-89362000	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	21755000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	68723000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-17545000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-13500000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-69124000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-50927000	usd
CY2024Q3	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	5915000	usd
CY2023Q3	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	5479000	usd
	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	17348000	usd
	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	16047000	usd
CY2024Q3	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	2721000	usd
CY2023Q3	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	3815000	usd
	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	8629000	usd
	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	11129000	usd
CY2024Q3	urgn	Interest And Other Income Net InterestAndOtherIncomeNet	2599000	usd
CY2023Q3	urgn	Interest And Other Income Net InterestAndOtherIncomeNet	906000	usd
	urgn	Interest And Other Income Net InterestAndOtherIncomeNet	5922000	usd
	urgn	Interest And Other Income Net InterestAndOtherIncomeNet	1941000	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23582000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-76162000	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	91000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-9000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	183000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	66000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-23673000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-21879000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-89362000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-76228000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-23673000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-89362000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-76228000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	267000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	20000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	224000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-27000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20852000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	59183000	usd
CY2024Q3	us-gaap	Cost Of Revenue CostOfRevenue	2453000	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	2367000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	6410000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	7075000	usd
CY2024Q3	us-gaap	Gross Profit GrossProfit	22751000	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	18485000	usd
	us-gaap	Gross Profit GrossProfit	59423000	usd
	us-gaap	Gross Profit GrossProfit	52108000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11355000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10230000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	42251000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	34312000	usd
CY2024Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	28941000	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	21755000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	86296000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	68723000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-17545000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-13500000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-50927000	usd
CY2024Q3	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	5915000	usd
CY2023Q3	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	5479000	usd
	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	17348000	usd
	dei	Entity Registrant Name EntityRegistrantName	UroGen Pharma Ltd.
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42190815
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	42190815
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	32490119
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32490119
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	30314000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	267000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-23673000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-138434000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	18000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-65212000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-89362000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-89361000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	833000	usd
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	42200000
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32500000
CY2024Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3200000	usd
CY2024Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	1200000	usd
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38079
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	IL
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1460746
	dei	Entity Address Address Line1 EntityAddressAddressLine1	400 Alexander Park Drive
	dei	Entity Address City Or Town EntityAddressCityOrTown	Princeton
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	08540
	dei	City Area Code CityAreaCode	646
	dei	Local Phone Number LocalPhoneNumber	768-9780
	dei	Security12b Title Security12bTitle	Ordinary Shares, par value NIS 0.01 per share
	dei	Trading Symbol TradingSymbol	URGN
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	42199414
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	124916000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	95002000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	124659000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	41966000	usd
CY2024Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	1073000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	821000	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	22802000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15443000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	7594000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	5673000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	14053000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10281000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	295097000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	169186000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	608000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	689000	usd
CY2024Q3	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	175000	usd
CY2023Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	225000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1052000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1671000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	4641000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	4502000	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	370000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2038000	usd
CY2024Q3	us-gaap	Assets Assets	301943000	usd
CY2023Q4	us-gaap	Assets Assets	178311000	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	19685000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	16538000	usd
CY2024Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9029000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	10814000	usd
CY2024Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	4073000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3860000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	32787000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	31212000	usd
CY2024Q3	urgn	Prepaid Forward Obligation PrepaidForwardObligation	118526000	usd
CY2023Q4	urgn	Prepaid Forward Obligation PrepaidForwardObligation	109722000	usd
CY2024Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	121709000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	98551000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	212000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	844000	usd
CY2024Q3	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	3194000	usd
CY2023Q4	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	3194000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	276428000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	243523000	usd
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	115000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	89000	usd
CY2024Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	793874000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	614035000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-768710000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-679348000	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	236000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	12000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	25515000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-65212000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	301943000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	178311000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	25204000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20852000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	65833000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	59183000	usd
CY2024Q3	us-gaap	Cost Of Revenue CostOfRevenue	2453000	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	2367000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	6410000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	7075000	usd
CY2024Q3	us-gaap	Gross Profit GrossProfit	22751000	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	18485000	usd
	us-gaap	Gross Profit GrossProfit	59423000	usd
	us-gaap	Gross Profit GrossProfit	52108000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11355000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10230000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	34312000	usd
CY2024Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	28941000	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	21755000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	86296000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	68723000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-17545000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-13500000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-69124000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-50927000	usd
CY2024Q3	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	5915000	usd
CY2023Q3	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	5479000	usd
	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	17348000	usd
	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	16047000	usd
CY2024Q3	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	2721000	usd
CY2023Q3	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	3815000	usd
	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	8629000	usd
	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	11129000	usd
CY2024Q3	urgn	Interest And Other Income Net InterestAndOtherIncomeNet	2599000	usd
CY2023Q3	urgn	Interest And Other Income Net InterestAndOtherIncomeNet	906000	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23582000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21888000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-89179000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-76162000	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	91000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-9000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	183000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	66000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-23673000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-89362000	usd
	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	16047000	usd
CY2024Q3	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	2721000	usd
CY2023Q3	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	3815000	usd
	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	8629000	usd
	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	11129000	usd
CY2024Q3	urgn	Interest And Other Income Net InterestAndOtherIncomeNet	2599000	usd
CY2023Q3	urgn	Interest And Other Income Net InterestAndOtherIncomeNet	906000	usd
	urgn	Interest And Other Income Net InterestAndOtherIncomeNet	5922000	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23582000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-89179000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-9000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	183000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	66000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-21879000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-89362000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-76228000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-23673000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-89362000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-76228000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	267000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	20000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	224000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-27000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23406000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21859000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-89138000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-76255000	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.68
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.36
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.89
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43100237
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32298182
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37797492
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26358719
CY2024Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	115000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3489000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	15003000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	25515000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2224000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	48700000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	67358000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	20000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-21879000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-41993000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	250000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9805000	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	18641000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	151169000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	224000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	25515000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6732000	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	48700000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-76228000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-23673000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-21879000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-76228000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	267000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	20000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	224000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-27000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23406000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-76255000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.55
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.68
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.36
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.89
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43100237
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37797492
CY2024Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	115000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3489000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	15003000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	25515000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	67358000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-21879000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	250000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9805000	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	18641000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	151169000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	224000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	25515000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6732000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	67358000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-27000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-89362000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-76228000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	261000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	612000	usd
	urgn	Accrued Financing On Prepaid Forward Obligation AccruedFinancingOnPrepaidForwardObligation	8714000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1555000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	622000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	9805000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-1330000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	981000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	619000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	669000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1921000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	677000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	7359000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	143000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3772000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4937000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-1668000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-690000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3147000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1700000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-76228000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	267000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	20000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	224000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-27000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23406000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-89138000	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.68
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.36
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.89
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43100237
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32298182
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37797492
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26358719
CY2024Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	115000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3489000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	15003000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	25515000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	48700000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	67358000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-21879000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	250000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9805000	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	18641000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	151169000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	224000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	25515000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6732000	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	48700000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	67358000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-27000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-41993000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-89362000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-76228000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	261000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	612000	usd
	urgn	Accrued Financing On Prepaid Forward Obligation AccruedFinancingOnPrepaidForwardObligation	8714000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1555000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	622000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	9805000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	6732000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-1330000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	981000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	619000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1921000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	677000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	7359000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	143000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3772000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4937000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-1668000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-690000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1700000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23406000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-76255000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.55
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.68
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.36
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.89
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43100237
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37797492
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26358719
CY2024Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	115000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3489000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	15003000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	67358000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-21879000	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	18641000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	224000	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	48700000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	67358000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-27000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-76228000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-41993000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-89362000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-76228000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	261000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	612000	usd
	urgn	Accrued Financing On Prepaid Forward Obligation AccruedFinancingOnPrepaidForwardObligation	9013000	usd
	urgn	Accrued Financing On Prepaid Forward Obligation AccruedFinancingOnPrepaidForwardObligation	8714000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1555000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	622000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	6732000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-1330000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	619000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1921000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	7359000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	143000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3772000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4937000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-1668000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3147000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1700000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1785000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-626000	usd
	urgn	Increase Decrease In Restricted Deposits IncreaseDecreaseInRestrictedDeposits	50000	usd
	urgn	Increase Decrease In Restricted Deposits IncreaseDecreaseInRestrictedDeposits	0	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-83147000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-63380000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	118794000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	37740000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	45538000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	180000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-81234000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	833000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	24488000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	67358000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-76228000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-41993000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-89362000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-76228000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	261000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	612000	usd
	urgn	Accrued Financing On Prepaid Forward Obligation AccruedFinancingOnPrepaidForwardObligation	8714000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1555000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	6732000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-1330000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	981000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	619000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1921000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	677000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	7359000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	143000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3772000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4937000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-1668000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-690000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3147000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1700000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-626000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-766000	usd
	urgn	Increase Decrease In Restricted Deposits IncreaseDecreaseInRestrictedDeposits	50000	usd
	urgn	Increase Decrease In Restricted Deposits IncreaseDecreaseInRestrictedDeposits	0	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-83147000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-63380000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	118794000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	35009000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	37740000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	45538000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	180000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	138000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	10391000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	250000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	833000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	24488000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	18641000	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	48700000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	151169000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	67358000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	116891000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	30167000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	56220000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	125989000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1785000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-105000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-626000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-766000	usd
	urgn	Increase Decrease In Restricted Deposits IncreaseDecreaseInRestrictedDeposits	50000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-83147000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-63380000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	118794000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	37740000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	45538000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	180000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	138000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-81234000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	833000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	24488000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	18641000	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	48700000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	151169000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	67358000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	116891000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	30167000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	63902000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	56220000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	125989000	usd
	urgn	Non Cash New Lease Liabilities NonCashNewLeaseLiabilities	122000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-679300000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Actual results <em style="font: inherit;"> may </em>differ from those estimates. As applicable to the unaudited condensed consolidated financial statements, the critical accounting estimates relate to the fair value of share-based compensation, measurement of revenue, estimate of uncertain tax positions, and measurement of liabilities accounted for under the interest method.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p>
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-626000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-766000	usd
	urgn	Increase Decrease In Restricted Deposits IncreaseDecreaseInRestrictedDeposits	50000	usd
	urgn	Increase Decrease In Restricted Deposits IncreaseDecreaseInRestrictedDeposits	0	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-83147000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-63380000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	118794000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	35009000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	37740000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	45538000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	180000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-81234000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	10391000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	250000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	833000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	24488000	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	18641000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	151169000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	67358000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	194548000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	116891000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	30167000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	56220000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	125989000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	120122000	usd
	urgn	Non Cash New Lease Liabilities NonCashNewLeaseLiabilities	0	usd
	urgn	Non Cash New Lease Liabilities NonCashNewLeaseLiabilities	122000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">1</em> </b>–<b> Business and Nature of Operations</b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Nature of Operations</i></b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">UroGen Pharma Ltd. is an Israeli company incorporated in <em style="font: inherit;"> April 2004 (</em>“UPL”).</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">UroGen Pharma, Inc., a wholly owned subsidiary of UPL, was incorporated in Delaware in <em style="font: inherit;"> October 2015 </em>and began operating in <em style="font: inherit;"> February 2016 (</em>“UPI”).</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">UPL and UPI (together the “Company”) is a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers. Since commencing operations, the Company has devoted substantially all of its efforts to securing intellectual property rights, performing research and development activities, including conducting clinical trials and manufacturing activities, hiring personnel, launching the Company’s <em style="font: inherit;">first</em> commercial product, <i>Jelmyto</i> (mitomycin) for pyelocalyceal solution, formerly known as UGN-<em style="font: inherit;">101,</em> advancing UGN-<em style="font: inherit;">102</em> through regulatory approval, and raising capital to support and expand these activities.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">On <em style="font: inherit;"> April 15, 2020, </em>the U.S. Food and Drug Administration (“FDA”) granted expedited approval for <i>Jelmyto</i>, a <em style="font: inherit;">first</em>-in-class treatment indicated for adults with low-grade upper tract urothelial cancer. <i>Jelmyto</i> consists of mitomycin, an established chemotherapy, and sterile hydrogel, using our proprietary sustained release <i>RTGel</i> technology. It has been designed to prolong exposure of urinary tract tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In <em style="font: inherit;"> August 2024, </em>the Company completed the submission of the rolling NDA for UGN-<em style="font: inherit;">102.</em> In <em style="font: inherit;"> October 2024, </em>the FDA accepted the Company's NDA for UGN-<em style="font: inherit;">102</em> (mitomycin) for intravesical solution and assigned a Prescription Drug User Fee Act (PDUFA) goal date of <em style="font: inherit;"> June 13, 2025.</em></p>
	us-gaap	Basis Of Accounting BasisOfAccounting	<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">2</em> </b>–<b> Basis of Presentation</b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and in accordance with instructions to Form <em style="font: inherit;">10</em>-Q and Article <em style="font: inherit;">10</em> of Regulation S-<em style="font: inherit;">X.</em> Accordingly, they do <em style="font: inherit;">not</em> include all the information and footnotes required by GAAP for complete financial statements. In the opinion of the Company’s management, the accompanying condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals and adjustments) necessary for fair statement of its financial position, results of operations and cash flows of the Company at the dates and for the periods indicated. Interim results are <em style="font: inherit;">not</em> necessarily indicative of results for the full fiscal year. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does <em style="font: inherit;">not</em> include all disclosures required by accounting principles generally accepted in the United States. The unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto contained in the Company’s Annual Report on Form <em style="font: inherit;">10</em>-K for the year ended <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2023,</em> as filed with the U.S. Securities and Exchange Commission (“SEC”) on <em style="font: inherit;"> March 14, 2024.</em></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company has experienced net losses since its inception and has an accumulated deficit o<span style="background-color: rgb(255, 255, 255); font-family: Arial, Helvetica, sans-serif;">f $768.7 </span>million and $679.3 million as of <em style="font: inherit;"> September 30, 2024</em> and <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2023,</em> respectively. The Company expects to incur losses and have negative net cash flows from operating activities as it executes on its strategy including engaging in further research and development activities, particularly conducting non-clinical studies and clinical trials. The success of the Company depends on the ability to successfully commercialize its technologies to support its operations and strategic plan. </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In accordance with the accounting guidance related to the presentation of financial statements, management evaluates whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern for the next <em style="font: inherit;">12</em> months from the date the financial statements are issued. The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, and do <em style="font: inherit;">not</em> include any adjustments relating to the carrying amounts and classification of assets and liabilities that <em style="font: inherit;"> may </em>be necessary should the Company be unable to continue as a going concern. The Company’s ability to continue as a going concern is expected to be impacted by its ability to raise additional capital to fund its operations, produce cash inflows from <i>Jelmyto</i> product sales and advance UGN-<em style="font: inherit;">102</em> through regulatory approval. </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Based on the Company's cash, cash equivalents and marketable securities as of <em style="font: inherit;"> September 30, 2024</em>, together with management’s cash flow projections, the Company believes that it has sufficient cash and cash equivalents to fund its operations beyond <em style="font: inherit;">one</em> year from the issuance of these condensed consolidated financial statements. The Company <em style="font: inherit;"> may </em>need to raise additional capital in the future. There can be <em style="font: inherit;">no</em> assurances that the Company will be able to secure such additional financing on terms that are satisfactory to the Company, in an amount sufficient to meet the Company's needs, or at all. In the event the Company is <em style="font: inherit;">not</em> successful in obtaining sufficient funding, this could force the Company to delay, limit, or reduce the Company's product development, commercialization efforts or other operations.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p>
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-768700000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	18641000	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	48700000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	151169000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	67358000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	116891000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	95822000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	56220000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	125989000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	120122000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">1</em> </b>–<b> Business and Nature of Operations</b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Nature of Operations</i></b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">UroGen Pharma Ltd. is an Israeli company incorporated in <em style="font: inherit;"> April 2004 (</em>“UPL”).</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">UroGen Pharma, Inc., a wholly owned subsidiary of UPL, was incorporated in Delaware in <em style="font: inherit;"> October 2015 </em>and began operating in <em style="font: inherit;"> February 2016 (</em>“UPI”).</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">UPL and UPI (together the “Company”) is a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers. Since commencing operations, the Company has devoted substantially all of its efforts to securing intellectual property rights, performing research and development activities, including conducting clinical trials and manufacturing activities, hiring personnel, launching the Company’s <em style="font: inherit;">first</em> commercial product, <i>Jelmyto</i> (mitomycin) for pyelocalyceal solution, formerly known as UGN-<em style="font: inherit;">101,</em> advancing UGN-<em style="font: inherit;">102</em> through regulatory approval, and raising capital to support and expand these activities.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">On <em style="font: inherit;"> April 15, 2020, </em>the U.S. Food and Drug Administration (“FDA”) granted expedited approval for <i>Jelmyto</i>, a <em style="font: inherit;">first</em>-in-class treatment indicated for adults with low-grade upper tract urothelial cancer. <i>Jelmyto</i> consists of mitomycin, an established chemotherapy, and sterile hydrogel, using our proprietary sustained release <i>RTGel</i> technology. It has been designed to prolong exposure of urinary tract tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In <em style="font: inherit;"> August 2024, </em>the Company completed the submission of the rolling NDA for UGN-<em style="font: inherit;">102.</em> In <em style="font: inherit;"> October 2024, </em>the FDA accepted the Company's NDA for UGN-<em style="font: inherit;">102</em> (mitomycin) for intravesical solution and assigned a Prescription Drug User Fee Act (PDUFA) goal date of <em style="font: inherit;"> June 13, 2025.</em></p>
	us-gaap	Basis Of Accounting BasisOfAccounting	<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">2</em> </b>–<b> Basis of Presentation</b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and in accordance with instructions to Form <em style="font: inherit;">10</em>-Q and Article <em style="font: inherit;">10</em> of Regulation S-<em style="font: inherit;">X.</em> Accordingly, they do <em style="font: inherit;">not</em> include all the information and footnotes required by GAAP for complete financial statements. In the opinion of the Company’s management, the accompanying condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals and adjustments) necessary for fair statement of its financial position, results of operations and cash flows of the Company at the dates and for the periods indicated. Interim results are <em style="font: inherit;">not</em> necessarily indicative of results for the full fiscal year. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does <em style="font: inherit;">not</em> include all disclosures required by accounting principles generally accepted in the United States. The unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto contained in the Company’s Annual Report on Form <em style="font: inherit;">10</em>-K for the year ended <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2023,</em> as filed with the U.S. Securities and Exchange Commission (“SEC”) on <em style="font: inherit;"> March 14, 2024.</em></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company has experienced net losses since its inception and has an accumulated deficit o<span style="background-color: rgb(255, 255, 255); font-family: Arial, Helvetica, sans-serif;">f $768.7 </span>million and $679.3 million as of <em style="font: inherit;"> September 30, 2024</em> and <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2023,</em> respectively. The Company expects to incur losses and have negative net cash flows from operating activities as it executes on its strategy including engaging in further research and development activities, particularly conducting non-clinical studies and clinical trials. The success of the Company depends on the ability to successfully commercialize its technologies to support its operations and strategic plan. </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In accordance with the accounting guidance related to the presentation of financial statements, management evaluates whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern for the next <em style="font: inherit;">12</em> months from the date the financial statements are issued. The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, and do <em style="font: inherit;">not</em> include any adjustments relating to the carrying amounts and classification of assets and liabilities that <em style="font: inherit;"> may </em>be necessary should the Company be unable to continue as a going concern. The Company’s ability to continue as a going concern is expected to be impacted by its ability to raise additional capital to fund its operations, produce cash inflows from <i>Jelmyto</i> product sales and advance UGN-<em style="font: inherit;">102</em> through regulatory approval. </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Based on the Company's cash, cash equivalents and marketable securities as of <em style="font: inherit;"> September 30, 2024</em>, together with management’s cash flow projections, the Company believes that it has sufficient cash and cash equivalents to fund its operations beyond <em style="font: inherit;">one</em> year from the issuance of these condensed consolidated financial statements. The Company <em style="font: inherit;"> may </em>need to raise additional capital in the future. There can be <em style="font: inherit;">no</em> assurances that the Company will be able to secure such additional financing on terms that are satisfactory to the Company, in an amount sufficient to meet the Company's needs, or at all. In the event the Company is <em style="font: inherit;">not</em> successful in obtaining sufficient funding, this could force the Company to delay, limit, or reduce the Company's product development, commercialization efforts or other operations.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p>
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-768700000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Actual results <em style="font: inherit;"> may </em>differ from those estimates. As applicable to the unaudited condensed consolidated financial statements, the critical accounting estimates relate to the fair value of share-based compensation, measurement of revenue, estimate of uncertain tax positions, and measurement of liabilities accounted for under the interest method.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p>
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">1</em> </b>–<b> Business and Nature of Operations</b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Nature of Operations</i></b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">UroGen Pharma Ltd. is an Israeli company incorporated in <em style="font: inherit;"> April 2004 (</em>“UPL”).</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">UroGen Pharma, Inc., a wholly owned subsidiary of UPL, was incorporated in Delaware in <em style="font: inherit;"> October 2015 </em>and began operating in <em style="font: inherit;"> February 2016 (</em>“UPI”).</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">UPL and UPI (together the “Company”) is a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers. Since commencing operations, the Company has devoted substantially all of its efforts to securing intellectual property rights, performing research and development activities, including conducting clinical trials and manufacturing activities, hiring personnel, launching the Company’s <em style="font: inherit;">first</em> commercial product, <i>Jelmyto</i> (mitomycin) for pyelocalyceal solution, formerly known as UGN-<em style="font: inherit;">101,</em> advancing UGN-<em style="font: inherit;">102</em> through regulatory approval, and raising capital to support and expand these activities.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">On <em style="font: inherit;"> April 15, 2020, </em>the U.S. Food and Drug Administration (“FDA”) granted expedited approval for <i>Jelmyto</i>, a <em style="font: inherit;">first</em>-in-class treatment indicated for adults with low-grade upper tract urothelial cancer. <i>Jelmyto</i> consists of mitomycin, an established chemotherapy, and sterile hydrogel, using our proprietary sustained release <i>RTGel</i> technology. It has been designed to prolong exposure of urinary tract tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In <em style="font: inherit;"> August 2024, </em>the Company completed the submission of the rolling NDA for UGN-<em style="font: inherit;">102.</em> In <em style="font: inherit;"> October 2024, </em>the FDA accepted the Company's NDA for UGN-<em style="font: inherit;">102</em> (mitomycin) for intravesical solution and assigned a Prescription Drug User Fee Act (PDUFA) goal date of <em style="font: inherit;"> June 13, 2025.</em></p>
	us-gaap	Basis Of Accounting BasisOfAccounting	<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">2</em> </b>–<b> Basis of Presentation</b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and in accordance with instructions to Form <em style="font: inherit;">10</em>-Q and Article <em style="font: inherit;">10</em> of Regulation S-<em style="font: inherit;">X.</em> Accordingly, they do <em style="font: inherit;">not</em> include all the information and footnotes required by GAAP for complete financial statements. In the opinion of the Company’s management, the accompanying condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals and adjustments) necessary for fair statement of its financial position, results of operations and cash flows of the Company at the dates and for the periods indicated. Interim results are <em style="font: inherit;">not</em> necessarily indicative of results for the full fiscal year. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does <em style="font: inherit;">not</em> include all disclosures required by accounting principles generally accepted in the United States. The unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto contained in the Company’s Annual Report on Form <em style="font: inherit;">10</em>-K for the year ended <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2023,</em> as filed with the U.S. Securities and Exchange Commission (“SEC”) on <em style="font: inherit;"> March 14, 2024.</em></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company has experienced net losses since its inception and has an accumulated deficit o<span style="background-color: rgb(255, 255, 255); font-family: Arial, Helvetica, sans-serif;">f $768.7 </span>million and $679.3 million as of <em style="font: inherit;"> September 30, 2024</em> and <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2023,</em> respectively. The Company expects to incur losses and have negative net cash flows from operating activities as it executes on its strategy including engaging in further research and development activities, particularly conducting non-clinical studies and clinical trials. The success of the Company depends on the ability to successfully commercialize its technologies to support its operations and strategic plan. </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In accordance with the accounting guidance related to the presentation of financial statements, management evaluates whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern for the next <em style="font: inherit;">12</em> months from the date the financial statements are issued. The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, and do <em style="font: inherit;">not</em> include any adjustments relating to the carrying amounts and classification of assets and liabilities that <em style="font: inherit;"> may </em>be necessary should the Company be unable to continue as a going concern. The Company’s ability to continue as a going concern is expected to be impacted by its ability to raise additional capital to fund its operations, produce cash inflows from <i>Jelmyto</i> product sales and advance UGN-<em style="font: inherit;">102</em> through regulatory approval. </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Based on the Company's cash, cash equivalents and marketable securities as of <em style="font: inherit;"> September 30, 2024</em>, together with management’s cash flow projections, the Company believes that it has sufficient cash and cash equivalents to fund its operations beyond <em style="font: inherit;">one</em> year from the issuance of these condensed consolidated financial statements. The Company <em style="font: inherit;"> may </em>need to raise additional capital in the future. There can be <em style="font: inherit;">no</em> assurances that the Company will be able to secure such additional financing on terms that are satisfactory to the Company, in an amount sufficient to meet the Company's needs, or at all. In the event the Company is <em style="font: inherit;">not</em> successful in obtaining sufficient funding, this could force the Company to delay, limit, or reduce the Company's product development, commercialization efforts or other operations.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p>
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-768700000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	254200000	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Concentration of Credit Risk</i></b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and marketable securities. The primary objectives for the Company’s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does <em style="font: inherit;">not</em> enter into any investment transaction for trading or speculative purposes.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company’s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company’s product sales are recognized through the Company's arrangements with <em style="font: inherit;">third</em>-party national specialty distributors. The Company assesses the need for an allowance for doubtful accounts primarily based on creditworthiness, historical payment experience and general economic conditions. The Company has <em style="font: inherit;">not</em> experienced any credit losses related to arrangements with customers and has <em style="font: inherit;">not</em> currently recognized any allowance for doubtful accounts.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p>
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Actual results <em style="font: inherit;"> may </em>differ from those estimates. As applicable to the unaudited condensed consolidated financial statements, the critical accounting estimates relate to the fair value of share-based compensation, measurement of revenue, estimate of uncertain tax positions, and measurement of liabilities accounted for under the interest method.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p>
CY2024Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	254200000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	254200000	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Concentration of Credit Risk</i></b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and marketable securities. The primary objectives for the Company’s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does <em style="font: inherit;">not</em> enter into any investment transaction for trading or speculative purposes.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company’s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company’s product sales are recognized through the Company's arrangements with <em style="font: inherit;">third</em>-party national specialty distributors. The Company assesses the need for an allowance for doubtful accounts primarily based on creditworthiness, historical payment experience and general economic conditions. The Company has <em style="font: inherit;">not</em> experienced any credit losses related to arrangements with customers and has <em style="font: inherit;">not</em> currently recognized any allowance for doubtful accounts.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p>
CY2024Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	254200000	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Concentration of Credit Risk</i></b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and marketable securities. The primary objectives for the Company’s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does <em style="font: inherit;">not</em> enter into any investment transaction for trading or speculative purposes.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company’s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company’s product sales are recognized through the Company's arrangements with <em style="font: inherit;">third</em>-party national specialty distributors. The Company assesses the need for an allowance for doubtful accounts primarily based on creditworthiness, historical payment experience and general economic conditions. The Company has <em style="font: inherit;">not</em> experienced any credit losses related to arrangements with customers and has <em style="font: inherit;">not</em> currently recognized any allowance for doubtful accounts.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p>
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	5556000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6514000	usd
CY2024Q3	urgn	Accrued Sales Reserve Current AccruedSalesReserveCurrent	7695000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	5556000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6514000	usd
CY2024Q3	urgn	Accrued Sales Reserve Current AccruedSalesReserveCurrent	7695000	usd
CY2023Q4	urgn	Accrued Sales Reserve Current AccruedSalesReserveCurrent	4391000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	5556000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6514000	usd
CY2024Q3	urgn	Accrued Sales Reserve Current AccruedSalesReserveCurrent	7695000	usd
CY2023Q4	urgn	Accrued Sales Reserve Current AccruedSalesReserveCurrent	4391000	usd
CY2024Q3	urgn	Accrued Clinical Expense AccruedClinicalExpense	1094000	usd
CY2024Q3	urgn	Accrued Selling General And Administrative Expense AccruedSellingGeneralAndAdministrativeExpense	2763000	usd
CY2023Q4	urgn	Accrued Selling General And Administrative Expense AccruedSellingGeneralAndAdministrativeExpense	2752000	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1884000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	586000	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	19685000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	16538000	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	2757000	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	835000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	6089000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1915000	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-158000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	71000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-167000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	26000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	5556000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6514000	usd
CY2024Q3	urgn	Accrued Sales Reserve Current AccruedSalesReserveCurrent	7695000	usd
CY2023Q4	urgn	Accrued Sales Reserve Current AccruedSalesReserveCurrent	4391000	usd
CY2024Q3	urgn	Accrued Clinical Expense AccruedClinicalExpense	1094000	usd
CY2023Q4	urgn	Accrued Clinical Expense AccruedClinicalExpense	1246000	usd
CY2023Q4	urgn	Accrued Research And Development Expense AccruedResearchAndDevelopmentExpense	1049000	usd
CY2023Q4	urgn	Accrued Selling General And Administrative Expense AccruedSellingGeneralAndAdministrativeExpense	2752000	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1884000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	586000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	16538000	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	2757000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	6089000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1915000	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-158000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	71000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-167000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	26000	usd
CY2024Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	2599000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	5922000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	1941000	usd
CY2024Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4662000	usd
CY2024Q3	urgn	Accrued Clinical Expense AccruedClinicalExpense	1094000	usd
CY2023Q4	urgn	Accrued Research And Development Expense AccruedResearchAndDevelopmentExpense	1049000	usd
CY2024Q3	urgn	Accrued Selling General And Administrative Expense AccruedSellingGeneralAndAdministrativeExpense	2763000	usd
CY2023Q4	urgn	Accrued Selling General And Administrative Expense AccruedSellingGeneralAndAdministrativeExpense	2752000	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1884000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	586000	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	19685000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	16538000	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	2757000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	6089000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1915000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	71000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-167000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	26000	usd
CY2024Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	2599000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	1941000	usd
CY2024Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4662000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4464000	usd
CY2024Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2932000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2877000	usd
CY2024Q3	urgn	Inventory Current And Noncurrent Net InventoryCurrentAndNoncurrentNet	7594000	usd
CY2023Q4	urgn	Inventory Current And Noncurrent Net InventoryCurrentAndNoncurrentNet	7341000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	129065000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	239000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3000	usd
CY2023Q4	urgn	Accrued Clinical Expense AccruedClinicalExpense	1246000	usd
CY2024Q3	urgn	Accrued Research And Development Expense AccruedResearchAndDevelopmentExpense	693000	usd
CY2023Q4	urgn	Accrued Research And Development Expense AccruedResearchAndDevelopmentExpense	1049000	usd
CY2024Q3	urgn	Accrued Selling General And Administrative Expense AccruedSellingGeneralAndAdministrativeExpense	2763000	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1884000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	586000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	16538000	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	2757000	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	835000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	6089000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1915000	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-158000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	71000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	26000	usd
CY2024Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	2599000	usd
CY2023Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	906000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	5922000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	1941000	usd
CY2024Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4662000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4464000	usd
CY2024Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2932000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2877000	usd
CY2024Q3	urgn	Inventory Current And Noncurrent Net InventoryCurrentAndNoncurrentNet	7594000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	239000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3000	usd
CY2024Q3	us-gaap	Short Term Investments ShortTermInvestments	153934000	usd
CY2024Q3	urgn	Cash Cash Equivalents And Short Term Investments Accumulated Gross Unrealized Gain Before Tax CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax	239000	usd
CY2024Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	2599000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	1941000	usd
CY2024Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4662000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4464000	usd
CY2024Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2932000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2877000	usd
CY2024Q3	urgn	Inventory Current And Noncurrent Net InventoryCurrentAndNoncurrentNet	7594000	usd
CY2023Q4	urgn	Inventory Current And Noncurrent Net InventoryCurrentAndNoncurrentNet	7341000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	129065000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	239000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	129301000	usd
CY2024Q3	us-gaap	Short Term Investments ShortTermInvestments	153934000	usd
CY2024Q3	urgn	Cash Cash Equivalents And Short Term Investments Accumulated Gross Unrealized Gain Before Tax CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax	239000	usd
CY2024Q3	urgn	Cash Cash Equivalents And Short Term Investments Accumulated Gross Unrealized Losses Before Tax CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossesBeforeTax	3000	usd
CY2024Q3	urgn	Cash Cash Equivalents And Short Term Investments Fair Value Disclosure CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure	154170000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	4600000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	4	pure
CY2024Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	149528000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	51670000	usd
CY2024Q3	urgn	Debt Securities Availableforsale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Three DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree	4642000	usd
CY2023Q4	urgn	Debt Securities Availableforsale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Three DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree	4502000	usd
CY2024Q3	us-gaap	Investments Investments	154170000	usd
CY2023Q4	us-gaap	Investments Investments	56172000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4641000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3952000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4464000	usd
CY2024Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2932000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2877000	usd
CY2023Q4	urgn	Inventory Current And Noncurrent Net InventoryCurrentAndNoncurrentNet	7341000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	129065000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	239000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	129301000	usd
CY2024Q3	us-gaap	Short Term Investments ShortTermInvestments	153934000	usd
CY2024Q3	urgn	Cash Cash Equivalents And Short Term Investments Accumulated Gross Unrealized Gain Before Tax CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax	239000	usd
CY2024Q3	urgn	Cash Cash Equivalents And Short Term Investments Accumulated Gross Unrealized Losses Before Tax CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossesBeforeTax	3000	usd
CY2024Q3	urgn	Cash Cash Equivalents And Short Term Investments Fair Value Disclosure CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure	154170000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	4600000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	4	pure
CY2024Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	149528000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	51670000	usd
CY2024Q3	urgn	Debt Securities Availableforsale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Three DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree	4642000	usd
CY2023Q4	urgn	Debt Securities Availableforsale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Three DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree	4502000	usd
CY2024Q3	us-gaap	Investments Investments	154170000	usd
CY2023Q4	us-gaap	Investments Investments	56172000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4821000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4641000	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4213000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3952000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	689000	usd
CY2024Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	129301000	usd
CY2024Q3	us-gaap	Short Term Investments ShortTermInvestments	153934000	usd
CY2024Q3	urgn	Cash Cash Equivalents And Short Term Investments Accumulated Gross Unrealized Gain Before Tax CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax	239000	usd
CY2024Q3	urgn	Cash Cash Equivalents And Short Term Investments Accumulated Gross Unrealized Losses Before Tax CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossesBeforeTax	3000	usd
CY2024Q3	urgn	Cash Cash Equivalents And Short Term Investments Fair Value Disclosure CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure	154170000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	4	pure
CY2024Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	149528000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	51670000	usd
CY2024Q3	urgn	Debt Securities Availableforsale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Three DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree	4642000	usd
CY2023Q4	urgn	Debt Securities Availableforsale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Three DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree	4502000	usd
CY2024Q3	us-gaap	Investments Investments	154170000	usd
CY2023Q4	us-gaap	Investments Investments	56172000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4821000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4641000	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4213000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3952000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	608000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	689000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	300000	usd
CY2023Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	200000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	600000	usd
CY2022Q4	urgn	Prepaid Forward Obligation PrepaidForwardObligation	98923000	usd
CY2023	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	21552000	usd
CY2023	urgn	Decrease In Prepaid Forward Obligation Amounts Paid And Payable DecreaseInPrepaidForwardObligationAmountsPaidAndPayable	10753000	usd
CY2023Q4	urgn	Prepaid Forward Obligation PrepaidForwardObligation	109722000	usd
	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	17348000	usd
	urgn	Decrease In Prepaid Forward Obligation Amounts Paid And Payable DecreaseInPrepaidForwardObligationAmountsPaidAndPayable	8544000	usd
CY2024Q3	urgn	Prepaid Forward Obligation PrepaidForwardObligation	118526000	usd
CY2024Q3	urgn	Cash Cash Equivalents And Short Term Investments Fair Value Disclosure CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure	154170000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	4600000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	4	pure
CY2024Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	149528000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	51670000	usd
CY2023Q4	urgn	Debt Securities Availableforsale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Three DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree	4502000	usd
CY2023Q4	us-gaap	Investments Investments	56172000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4641000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3952000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	608000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	689000	usd
CY2024Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	300000	usd
CY2023Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	200000	usd
CY2022Q4	urgn	Prepaid Forward Obligation PrepaidForwardObligation	98923000	usd
CY2023	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	21552000	usd
	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	17348000	usd
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	225000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	675000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	710000	usd
CY2023Q3	us-gaap	Sublease Income SubleaseIncome	56000	usd
	us-gaap	Sublease Income SubleaseIncome	168000	usd
CY2024Q3	us-gaap	Variable Lease Cost VariableLeaseCost	14000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	51000	usd
CY2023Q3	us-gaap	Lease Cost LeaseCost	182000	usd
	us-gaap	Lease Cost LeaseCost	690000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1671000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	212000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	844000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	608000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	689000	usd
CY2024Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	300000	usd
CY2022Q4	urgn	Prepaid Forward Obligation PrepaidForwardObligation	98923000	usd
CY2023	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	21552000	usd
CY2024Q3	urgn	Prepaid Forward Obligation PrepaidForwardObligation	118526000	usd
CY2024Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	225000	usd
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	225000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	675000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	710000	usd
	us-gaap	Sublease Income SubleaseIncome	42000	usd
	us-gaap	Sublease Income SubleaseIncome	168000	usd
CY2024Q3	us-gaap	Variable Lease Cost VariableLeaseCost	14000	usd
CY2023Q3	us-gaap	Variable Lease Cost VariableLeaseCost	13000	usd
CY2024Q3	us-gaap	Lease Cost LeaseCost	239000	usd
CY2023Q3	us-gaap	Lease Cost LeaseCost	182000	usd
	us-gaap	Lease Cost LeaseCost	690000	usd
	us-gaap	Lease Cost LeaseCost	593000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1052000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1671000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	212000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	844000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	600000	usd
CY2022Q4	urgn	Prepaid Forward Obligation PrepaidForwardObligation	98923000	usd
CY2023	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	21552000	usd
CY2023	urgn	Decrease In Prepaid Forward Obligation Amounts Paid And Payable DecreaseInPrepaidForwardObligationAmountsPaidAndPayable	10753000	usd
	urgn	Decrease In Prepaid Forward Obligation Amounts Paid And Payable DecreaseInPrepaidForwardObligationAmountsPaidAndPayable	8544000	usd
CY2024Q3	urgn	Prepaid Forward Obligation PrepaidForwardObligation	118526000	usd
CY2024Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	225000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	675000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	710000	usd
CY2024Q3	us-gaap	Sublease Income SubleaseIncome	-0	usd
CY2023Q3	us-gaap	Sublease Income SubleaseIncome	56000	usd
	us-gaap	Sublease Income SubleaseIncome	42000	usd
	us-gaap	Sublease Income SubleaseIncome	168000	usd
CY2024Q3	us-gaap	Variable Lease Cost VariableLeaseCost	14000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	51000	usd
CY2024Q3	us-gaap	Lease Cost LeaseCost	239000	usd
	us-gaap	Lease Cost LeaseCost	690000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1671000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	844000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	825000	usd
CY2024Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	225000	usd
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	225000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	675000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	710000	usd
CY2024Q3	us-gaap	Sublease Income SubleaseIncome	-0	usd
	us-gaap	Sublease Income SubleaseIncome	42000	usd
CY2024Q3	us-gaap	Variable Lease Cost VariableLeaseCost	14000	usd
CY2023Q3	us-gaap	Variable Lease Cost VariableLeaseCost	13000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	57000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	51000	usd
CY2024Q3	us-gaap	Lease Cost LeaseCost	239000	usd
CY2023Q3	us-gaap	Lease Cost LeaseCost	182000	usd
	us-gaap	Lease Cost LeaseCost	690000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	212000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	844000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	825000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	819000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	714000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	878000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	122000	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y3M3D
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1026	pure
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1016	pure
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	825000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	819000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	714000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	878000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	122000	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y3M3D
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1026	pure
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1016	pure
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	219000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	820000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	58000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1097000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	60000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1037000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	291000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	923000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	813000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	57000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2084000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	200000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1884000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	825000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	819000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	714000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	878000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	122000	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1026	pure
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1016	pure
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	219000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	820000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	58000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1097000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	60000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1037000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	291000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	923000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	57000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2084000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1884000	usd
CY2023Q4	urgn	Accrued Sales Reserve AccruedSalesReserve	5971000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	714000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	878000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	122000	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y3M3D
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y1M9D
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1026	pure
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1016	pure
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	219000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	820000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	58000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	60000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1037000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	291000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	923000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	813000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	57000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2084000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	200000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1884000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	219000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	58000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1097000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	60000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1037000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	291000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	923000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	813000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2084000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1884000	usd
	urgn	Sales Reserve Accruals SalesReserveAccruals	20649000	usd
CY2024Q3	urgn	Accrued Sales Reserve AccruedSalesReserve	9195000	usd
CY2023Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	120000000	usd
CY2023Q4	urgn	Accrued Sales Reserve AccruedSalesReserve	5971000	usd
	urgn	Sales Reserve Accruals SalesReserveAccruals	20649000	usd
	urgn	Sales Reserve Utilization SalesReserveUtilization	-17425000	usd
CY2024Q3	urgn	Accrued Sales Reserve AccruedSalesReserve	9195000	usd
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2023Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	120000000	usd
CY2024Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3961302
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1853992
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3489000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2224000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9805000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6732000	usd
	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	0	usd
CY2023Q4	urgn	Accrued Sales Reserve AccruedSalesReserve	5971000	usd
CY2024Q3	urgn	Accrued Sales Reserve AccruedSalesReserve	9195000	usd
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2023Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	120000000	usd
CY2024Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3961302
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1853992
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3489000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2224000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9805000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6732000	usd
	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	0	usd
	urgn	Sales Reserve Utilization SalesReserveUtilization	-17425000	usd
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2023Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	120000000	usd
CY2024Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3961302
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1853992
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3489000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2224000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9805000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6732000	usd
CY2024Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	15100000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y9M25D
	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	0	usd
CY2024Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3961302
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1853992
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3489000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9805000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6732000	usd
CY2024Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	15100000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y9M25D
	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	0	usd

Files In Submission

Name	View Source	Status
0001437749-24-033454-index-headers.html	Edgar Link	pending
0001437749-24-033454-index.html	Edgar Link	pending
0001437749-24-033454.txt	Edgar Link	pending
0001437749-24-033454-xbrl.zip	Edgar Link	pending
ex_718343.htm	Edgar Link	pending
ex_718344.htm	Edgar Link	pending
ex_718345.htm	Edgar Link	pending
ex_718346.htm	Edgar Link	pending
ex_718347.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
urgn-20240930.xsd	Edgar Link	pending
urgn20240930c_10q.htm	Edgar Link	pending
urgn-20240930_cal.xml	Edgar Link	unprocessable
urgn-20240930_def.xml	Edgar Link	unprocessable
urgn-20240930_lab.xml	Edgar Link	unprocessable
urgn-20240930_pre.xml	Edgar Link	unprocessable
urgn20240930c_10q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$URGN
UroGen Pharma Ltd. Stock $urgn

2024 Q4 Form 10-Q Financial Statement

#000143774924033454 Filed on November 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$URGN UroGen Pharma Ltd. Stock $urgn

2024 Q4 Form 10-Q Financial Statement

#000143774924033454 Filed on November 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$URGN
UroGen Pharma Ltd. Stock $urgn